Drugs / Welgenaleucel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04296461 | Jul 2020 → Jun 2021 | B-cell non-Hodgkin lymphoma | UWELL Biopharma | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03811457 | Jun 2017 → Dec 2018 | lymphoid hemopathy | UWELL Biopharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Welgenaleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04296461 ↗ |
| Known as | UWC19 | “Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells” NCT03811457 ↗ |
| Modality | Cell therapy | “Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells” NCT03811457 ↗ |
| Route | Intravenous | “administered intravenously once.” NCT04296461 ↗ |
| Target | CD19 | “target cells that express CD19” NCT04296461 ↗ |